Clinical Trial

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-13.
Trial Details
NCT Number NCT05768529
Lead Sponsor Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Conditions Relapsed or Refractory Non-Hodgkin's Lymphoma
Enrollment 100 participants
Start Date 2023-03-28
Primary Completion 2024-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-21